IN THE CLAIMS

The listing of the claims which follows replaces any and all prior versions and/or listings of the claims in the application.

Claim 1 (currently amended): A compressed tablet comprising: efavirenz, filler/disintegrant, filler, superdisintegrant, binder, surfactant, diluent/compression aid, lubricant, and solvent, wherein efavirenz is from about 1 to about 75% by weight of the total composition of the compressed tablet, and the superdisintegrant has a concentration in the tablet between about 1% to about 5% by weight.

Claim 2 (previously presented): The compressed tablet, as recited in Claim 1, wherein the filler comprises: lactose, calcium carbonate, calcium sulfate, a compressible sugar, a dextrate, dextrin, dextrose, calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin mannitol, powdered cellulose, pregelatinized starch, or sucrose.

Claim 3 (currently amended): The compressed tablet, as recited in Claim 2, wherein the disintegrant and superdisintegrant each comprise: comprises alginic acid, earboxymethylcellulose calcium, carboxymethylcellulose sodium, colloidal silicon dioxide, croscarmellose sodium, crospovidone, guar gum, magnesium aluminum silicate, methylcellulose, microcrystalline cellulose, polyacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate or pregelatinized starch.

Claim 4 (previously presented): The compressed tablet, as recited in Claim 3, wherein the binder comprises: acacia, alginic acid, carbomer, dextrin, ethylcellulose, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, a polymethacrylate, povidone, pregelatinized starch, sodium alginate, starch, or zein.

Claim 5 (previously presented): The compressed tablet, as recited in Claim 4, wherein the surfactant comprises: sodium lauryl sulfate, docusate sodium, benzalkonium chloride, benzethonium chloride, or cetrimide.

Claim 6 (previously presented): The compressed tablet, as recited in Claim 5, wherein the filler/compression aid comprises: calcium carbonate, calcium sulfate, a compressible sugar, confectioner's sugar, a dextrate, dextrin, dextrose, dibasic calcium phosphate dihydrate, glyceryl palmitostearate, hydrogenated vegetable oil (type I), kaolin,

lactose, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, a polymethacrylate, potassium chloride, powdered cellulose, pregelatinized starch, sodium chloride, sorbitol, starch, sucrose, sugar spheres, talc or tribasic calcium phosphate.

Claim 7 (previously presented): The compressed tablet, as recited in Claim 6, wherein the lubricant comprises: calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, light mineral oil, magnesium stearate, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc or zinc stearate.

Claim 8 (original): The compressed tablet, as recited in Claim 7, wherein the solvent comprises: water, ethanol or mixtures thereof.

Claim 9 (currently amended): The compressed tablet, as recited in Claim 8, wherein the filler/disintegrant filler is a microcrystalline cellulose.

Claim 10 (original): The compressed tablet, as recited in Claim 9, wherein the superdisintegrant is a croscarmellose sodium.

Claim 11 (original): The compressed tablet, as recited in Claim 10, wherein the binder is a hydroxypropyl cellulose.

Claim 12 (original): The compressed tablet, as recited in Claim 11, wherein the surfactant is a sodium lauryl sulfate.

Claim 13 (original): The compressed tablet, as recited in Claim 12, wherein the filler/compression aid is a lactose hydrous spray dried.

Claim 14 (original): The compressed tablet, as recited in Claim 13, wherein the lubricant is a magnesium stearate.

Claim 15 (original): The compressed tablet, as recited in Claim 14, comprising efavirenz, microcrystalline cellulose NF, hydroxypropyl cellulose LF NF, croscarmellose sodium, sodium lauryl sulfate, lactose hydrous spray dried (EG), and magnesium stearate (EG).

Claim 16 (original): The compressed tablet, as recited in Claim 15, containing about 300 mg of efavirenz, about 120 mg microcrystalline cellulose NF, about 19.2 mg hydroxypropyl cellulose LF NF, about 30 mg croscarmellose sodium, about 6 mg sodium lauryl sulfate, about 118.8 mg lactose hydrous spray dried (EG), and about 6 mg magnesium stearate (EG).

Claims 17-25 (canceled)

Claim 26 (currently amended): A compressed tablet comprising: efavirenz, filler/disintegrant, filler, superdisintegrant, binder, surfactant, diluent/compression aid, lubricant, and solvent, wherein efavirenz is about 50% by weight of the total composition of the compressed tablet, and the superdisintegrant has a concentration in the tablet between about 1% to about 5% by weight.

Claim 27 (previously presented): The compressed tablet as recited in Claim 26, wherein efavirenz is present in an amount of about 300 mg.

Claim 28 (previously presented): The compressed tablet as recited in Claim 26, wherein efavirenz is present in an amount of about 600 mg.

Claim 29 (previously presented): The compressed tablet as recited in Claim 26, wherein the solvent comprises: water, ethanol or mixtures thereof.

Claim 30 (currently amended): The compressed tablet as recited in Claim 29, wherein the filler/disintegrant filler is a microcrystalline cellulose.

Claim 31 (previously presented): The compressed tablet as recited in Claim 30, wherein the superdisintegrant is a croscarmellose sodium.

Claim 32 (previously presented): The compressed tablet as recited in Claim 31, wherein the croscarmellose sodium is about 5% by weight of the total composition of the compressed tablet.

Claim 33 (currently amended): The compressed tablet as recited in Claim 31, wherein the binder is a hydroxypropyl cellulose. wherein:

the solvent comprises: water, ethanol or mixtures thereof;

the filler is a microcrystalline cellulose;
the superdisintegrant is a croscarmellose sodium;
the binder is a hydroxypropyl cellulose;
the surfactant is a sodium lauryl sulfate;
the filler/compression aid is a lactose hydrous spray dried; and
the lubricant is a magnesium stearate.

Claim 34 (currently amended): The compressed tablet as recited in Claim 33, wherein the surfactant is a sodium lauryl sulfate. efavirenz is present in an amount of about 300 mg.

Claim 35 (currently amended): The compressed tablet as recited in Claim 34, wherein the filler/compression aid is a lactose hydrous spray dried. Claim 33, wherein efavirenz is present in an amount of about 600 mg.

Claim 36 (canceled)

Claim 37 (currently amended): A compressed tablet comprising: efavirenz, filler/disintegrant, filler, superdisintegrant, binder, surfactant, diluent/compression aid, lubricant, and solvent; wherein efavirenz is from about 1 to about 75% by weight of the total composition of the compressed tablet, and the superdisintegrant has a concentration in the tablet between about 1% to about 5% by weight; and wherein the compressed tablet is prepared via wet granulation in which efavirenz, filler/disintegrant, filler, superdisintegrant, binder, and surfactant are blended intragranularly, and filler/compression aid and lubricant are added extragranularly.

Claim 38 (previously presented): The compressed tablet as recited in Claim 37, wherein efavirenz is about 50% by weight of the total composition of the compressed tablet.

Claim 39 (currently amended): The compressed tablet as recited in Claim [[37,]] 38, wherein efavirenz is present in an amount of about 300 mg.

Claim 40 (currently amended): The compressed tablet as recited in Claim [37,] 38, wherein efavirenz is present in an amount of about 600 mg.

Claim 41 (currently amended):

The compressed tablet as recited in Claim

[[37,]] <u>38,</u> wherein:

the solvent comprises: water, ethanol or mixtures thereof; the filler/disintegrant filler is a microcrystalline cellulose; the superdisintegrant is a croscarmellose sodium; the binder is a hydroxypropyl cellulose; the surfactant is a sodium lauryl sulfate; the filler/compression aid is a lactose hydrous spray dried; and the lubricant is a magnesium stearate.

Claim 42 (previously presented): The compressed tablet as recited in Claim 1, wherein the efavirenz is crystalline.

Claim 43 (previously presented): The compressed tablet as recited in Claim 26, wherein the efavirenz is crystalline.

Claim 44 (previously presented): The compressed tablet as recited in Claim 37, wherein the efavirenz is crystalline.

Claim 45 (new): The compressed tablet as recited in Claim 38, wherein the efavirenz is crystalline.

Claim 46 (new): The compressed tablet as recited in Claim 41, wherein efavirenz is present in an amount of about 300 mg.

Claim 47 (new): The compressed tablet as recited in Claim 41, wherein efavirenz is present in an amount of about 600 mg.